Physician profile
Ryan W Candee
NPI 1285042226
$5,486.45
in general payments reported to CMS, 2019-2025
46 companies · $22.26 in 2025
The $22.26 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,968 · 2022: $1,605 · 2023: $1,560 · 2024: $331 · 2025: $22.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $836.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $597.83 | 2021-2023 | Farxiga, Fasenra, Tezspire |
| Novo Nordisk INC | $395.01 | 2021-2023 | Ozempic, Rybelsus |
| Amgen INC. | $376.96 | 2021-2022 | |
| Gilead Sciences, INC. | $375.52 | 2021-2024 | Epclusa |
| Alexion Pharmaceuticals, INC. | $334.31 | 2021-2023 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $283.41 | 2022-2023 | |
| Boston Scientific Corporation | $220.70 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.27 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $180.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $164.12 | 2021-2023 | Xarelto |
| Optinose US, INC. | $121.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $116.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.97 | 2021 | |
| Inspire Medical Systems, INC. | $109.45 | 2023 | Inspire |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Candee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.